A detailed history of Jpmorgan Chase & CO transactions in Astrazeneca PLC stock. As of the latest transaction made, Jpmorgan Chase & CO holds 3,983,851 shares of AZN stock, worth $311 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
3,983,851
Previous 3,542,410 12.46%
Holding current value
$311 Million
Previous $239 Million 13.13%
% of portfolio
0.02%
Previous 0.02%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

BUY
$61.03 - $69.57 $26.9 Million - $30.7 Million
441,441 Added 12.46%
3,983,851 $270 Million
Q4 2023

Feb 12, 2024

BUY
$61.89 - $69.28 $92.5 Million - $104 Million
1,494,899 Added 73.01%
3,542,410 $239 Million
Q3 2023

Nov 14, 2023

SELL
$64.85 - $71.7 $1.89 Million - $2.09 Million
-29,081 Reduced 1.4%
2,047,511 $139 Million
Q2 2023

Aug 11, 2023

SELL
$69.91 - $75.81 $41 Million - $44.4 Million
-586,256 Reduced 22.02%
2,076,592 $149 Million
Q1 2023

May 11, 2023

SELL
$63.15 - $71.6 $42.6 Million - $48.3 Million
-674,329 Reduced 20.21%
2,662,848 $185 Million
Q4 2022

Feb 13, 2023

BUY
$54.21 - $70.44 $83.8 Million - $109 Million
1,545,443 Added 86.25%
3,337,177 $226 Million
Q3 2022

Nov 14, 2022

BUY
$53.02 - $135.75 $50.8 Million - $130 Million
958,359 Added 115.0%
1,791,734 $98.3 Million
Q2 2022

Aug 11, 2022

BUY
$59.26 - $71.14 $10 Million - $12 Million
169,380 Added 25.51%
833,375 $55.1 Million
Q1 2022

May 11, 2022

BUY
$55.72 - $67.12 $14.7 Million - $17.7 Million
263,929 Added 65.97%
663,995 $44 Million
Q4 2021

Feb 10, 2022

SELL
$54.02 - $63.83 $60.2 Million - $71.2 Million
-1,115,017 Reduced 73.59%
400,066 $23.3 Million
Q3 2021

Nov 12, 2021

BUY
$55.56 - $60.79 $84.2 Million - $92.1 Million
1,515,083 New
1,515,083 $91 Million

Others Institutions Holding AZN

About ASTRAZENECA PLC


  • Ticker AZN
  • Exchange OTC
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 3,099,020,032
  • Market Cap $242B
  • Description
  • AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, By...
More about AZN
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.